
    
      Patients must with Her2+(ErbB2+) MBC Stage IV, newly diagnosed will receive
      paclitaxel+lapatinib or paclitaxel plus placebo for 6 cycles minimum. After 6 cycles continue
      to receive blinded monotherapy until progression. Safety evaluations include evaluating
      adverse events, hematology/ chemistry tests, vital signs, and cardiac muga scans. Efficacy
      assessments include evaluation of disease per RECIST. All patients followed for overall
      survival (OS).

      Study conducted in regions were access to trastuzumab is limited.
    
  